Dry eye disease (DED) impacts countless individuals, and while therapies like Xiidra® (lifitegrast ophthalmic solution) 5% have proven effective,1 ensuring consistent patient compliance remains a challenge for eye care professionals. Xiidra, which can improve signs and symptoms as early as two weeks,1* is most effective when used consistently. Based on insights shared in the Defocus Media podcast, this article explores practical approaches to improving patient compliance through clear communication, setting expectations, and proactive patient engagement.

DED is often a chronic, life-impacting condition requiring ongoing management. Patients may not immediately see the value in treating DED, and misunderstandings can cause non-compliance. Xiidra® (lifitegrast ophthalmic solution) 5% can reduce symptoms like dryness and irritation within weeks,1* but adherence is critical to achieving these benefits.

As Dr. Jennifer Lyerly noted, explaining the purpose and potential impact of Xiidra is essential to helping patients appreciate its role in long-term ocular health. By emphasizing that regular use can yield noticeable improvements, providers can help patients see the value in their commitment to treatment.

Communication is foundational to compliance. Patients need to understand not only their diagnosis but also how Xiidra fits into their overall treatment plan. As Dr. Darryl Glover shared, a well-communicated plan includes a positive, reassuring approach: “I got your back; no worries, we’re in this together.” Language like this reassures patients that their provider is invested in their success and encourages them to stick with the treatment.

Tips for Effective Communication:

Follow-up visits are a powerful tool for reinforcing compliance. Dr. Glover explained that scheduling a follow-up visit provides a critical opportunity to assess patient progress, troubleshoot any issues, and encourage long-term adherence. He also shared that adding a touch of humor or personalization can make follow-up instructions feel less prescriptive and more collaborative, helping patients feel at ease and engaged with their treatment.

Dr. Mark Schaefer emphasized that these visits allow both patient and provider to witness the benefits of Xiidra. Dr. Schaefer noted, “Seeing the medication work builds confidence for both the patient and my staff.” The positive reinforcement patients receive during follow-ups can significantly boost compliance rates.

Pro-Tip: For patients who may be less consistent, consider adding a quick courtesy call from a staff member between appointments to check-in. This small gesture reminds patients that their eye care team is dedicated to their success.

One of the main reasons patients discontinue treatment is unexpected side effects. Dr. Schaefer highlighted the importance of preparing patients for what they might experience, including mild burning, blurred vision, or a temporary altered taste.1 He explained, “Under-promise and over-deliver. Patients are pleasantly surprised if they don’t experience any side effects or find them mild.”

Dr. Lyerly echoed this sentiment, noting that patients are less likely to be alarmed when side effects are normalized. By discussing these possibilities upfront, practitioners can preemptively address concerns, reducing the risk of patients abandoning treatment early.

Connecting Xiidra use with daily habits, like brushing teeth, is an effective way to encourage adherence. Dr. Glover shared that he often advises patients to use Xiidra when brushing their teeth, making it part of a routine they already follow.

Cost can be another barrier to compliance. Dr. Schaefer and Dr. Glover discussed strategies to ease the cost burden, including partnering with specialty pharmacies or using services such as BlinkRx. These resources simplify the prescription process and help patients obtain the medication at a lower cost, reducing abandonment rates.

For patients with cost concerns, Dr. Glover suggests stating, “If it’s too much, call me. We’ll figure something out.” This reassures patients that they won’t have to navigate cost concerns alone, strengthening their trust in the provider.

Ensuring compliance with Xiidra is a blend of patient education, empathy, and effective follow-up. When patients understand their treatment and feel supported, they’re more likely to adhere to the regimen. By setting clear expectations, building trust, and providing the resources they need, eye care professionals can help patients achieve lasting relief and healthier eyes.

Dr. Schaefer reminds us, “You’re going to workshop this and improve your approach with every patient.” Ultimately, compliance is not just about adhering to a treatment plan; it’s about fostering a trusting relationship where patients feel empowered and confident in their care.

INDICATION

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED). 

IMPORTANT SAFETY INFORMATION

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Prescribing Information for Xiidra at XIIDRA-ECP.COM.

References:

1. Xiidra. Prescribing Information. Bausch & Lomb Inc.

©2026 Bausch + Lomb. XDR.0029.USA.26